This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cori disease / Forbes disease / GSD type III / Debranching enzyme deficiency코리병 / 포르브스병

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.0 | Special Copayment Reduction: V117
B. SynonymsCori disease, Forbes disease, glycogen storage disease type III (GSD type III), debranching enzyme deficiency, amylo-1,6-glucosidase deficiency, AGL deficiency
C. Adult onsetLikelihood of first onset in adulthood moderate — it is often diagnosed in childhood from hypoglycemia and hepatomegaly, but in GSD type IIIa, as liver symptoms improve after puberty, myopathy comes to the fore, and it is sometimes first recognized and diagnosed in adulthood. Cases in which cardiomyopathy first presents as heart failure in adulthood have also been reported.
1. History1952: the Coris classified GSD III independently → 1956: Forbes described it independently → 1980s: AGL gene studies → 1993: AGL gene cloned → GSD IIIa/b/c/d subtypes established.
2. CausesAGL gene mutations → glycogen debranching enzyme (GDE) deficiency → incomplete glycogen breakdown → accumulation of abnormal glycogen (limit dextrin). Autosomal recessive.
3. GeneticsAGL: 1p21.2, 35 exons. GSD IIIa: liver + muscle involvement (many variants in exons 3–35). GSD IIIb: liver involvement only (exon 3 variants). North African Jews: frequent p.Q6X, p.W2 founder variants. Data on common variants in Korea are limited. More than about 200 pathogenic variants reported.
4. General epidemiologyPrevalence about 1/100,000. GSD III accounts for about 24% of all GSD, the second most common GSD. Frequent in North African Jews (about 1/5,400). GSD IIIa about 80%, IIIb about 15%. Many reports worldwide and in Asia.
5. PathophysiologyGDE deficiency → inability to remove the α-1,6 branches of glycogen → accumulation of limit dextrin (liver, muscle, myocardium). Glycogen breakdown is partly possible but stops at limit dextrin → fasting hypoglycemia (milder than GSD I). Limit dextrin accumulation in muscle and myocardium → myopathy and cardiomyopathy.
6. SymptomsChildhood: fasting hypoglycemia (milder than GSD I), hepatomegaly, growth retardation. Adolescence to adulthood (IIIa): proximal muscle weakness, exercise intolerance. Cardiomyopathy (hypertrophic or dilated). IIIb: liver symptoms predominate, no muscle involvement.
7. SignsHepatomegaly (confirmed by ultrasound), CK elevation (marked with muscle involvement), fasting hypoglycemia (milder than GSD I, may be accompanied by ketosis), partially preserved glucagon response (unlike GSD I). ECG abnormalities, echocardiography (hypertrophic cardiomyopathy). Electromyography (myopathic pattern).
8. ScreeningFasting metabolic profile (normal glucose, ketones, and amino acids vs. differentiation from the lactic acidosis pattern of GSD I), CK measurement, liver function tests. Genetic testing based on family history. Newborn screening is not standard (clinical judgment needed, including differentiation from GSD I).
9. DiagnosisBiochemistry: fasting hypoglycemia + CK elevation + ketosis (differentiation from GSD I). Glucagon stimulation: postprandial blood glucose may rise (unlike GSD I, gluconeogenesis partly works). Measurement of GDE enzyme activity in leukocytes or muscle. AGL gene analysis. Liver biopsy (histology).
10. TreatmentChildhood: maintain blood glucose with frequent high-carbohydrate meals or uncooked cornstarch. High-protein diet (muscle protection, supply of gluconeogenic precursors). Adult myopathy: physical therapy, exercise therapy. Cardiomyopathy: standard heart failure drug therapy. Liver transplantation if liver fibrosis/cirrhosis progresses. Gene therapy at the research stage.
11. PrognosisLiver symptoms tend to improve spontaneously after adolescence. In GSD IIIa, adult myopathy and cardiomyopathy are the main long-term morbidities. Risk of liver fibrosis → cirrhosis → hepatocellular carcinoma (also occurs in IIIa compared with IIIb). Overall life expectancy tends to be better than in GSD I, but individual variation is large.
12. PreventionEducation on preventing hypoglycemic emergencies, limiting fasting time, regular follow-up of cardiac function (echocardiography), liver function and imaging follow-up, genetic counseling, maintaining a high-protein, complex-carbohydrate diet.
13. ReferencesSentner CP et al. J Inherit Metab Dis 2016 and 9 others

1. History

Cori disease (GSD type III) was first described in 1952 by Gerty Cori and Carl Cori. While systematically classifying hepatic glycogen storage diseases by type of enzyme deficiency, they named as type III a disease, distinct from GSD I with glucose-6-phosphatase deficiency, in which only the outer chain portion of glycogen can be broken down and breakdown stops at the branch points. The abnormal glycogen structure that accumulates in this disease was called 'limit dextrin', a name that intuitively expresses the core of the disease's pathogenic mechanism.

In the same year, Gilbert Forbes in the United States independently described pediatric patients with a similar phenotype, so the synonym 'Forbes disease' is also used. Forbes emphasized the clinical difference that it is characterized by hepatomegaly and mild hypoglycemia but, unlike GSD I, may be accompanied by fasting ketosis.

In the 1960s–70s, the biochemical mechanism of the glycogen debranching enzyme (GDE) was elucidated. GDE was found to be a bifunctional enzyme with two enzymatic activities, amylo-1,6-glucosidase and oligo-1,4→1,4-glucan transferase, within a single polypeptide. Biochemical studies in the 1970s–80s confirmed that subtypes are distinguished according to selective deficiency of these enzymatic activities (IIIc: deficiency of glucosidase activity only; IIId: deficiency of transferase activity only — these two subtypes are very rare).

In 1993, the AGL gene (1p21.2, 35 exons) was cloned by Yamauchi et al. Founder variants were subsequently identified in certain ethnic groups: in North African Jews (Sephardic/North African Jewish, not the Ashkenazi Jewish population), the frequency of GSD IIIa is very high at about 1/5,400, and founder variants such as p.Q6X (c.16C>T, exon 3) were identified. As different variant spectra have been reported in various ethnic groups, a global variant database is being built.

Clinically, it was established through long-term follow-up studies in the 1980s–90s that in GSD IIIa, liver symptoms improve spontaneously after childhood, but myopathy and cardiomyopathy come to the fore in adulthood. This led to a shift in clinical perception of GSD III from a childhood liver disease only to an adult musculoskeletal disease. Long-term follow-up also confirmed the risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma, highlighting the importance of liver monitoring in adulthood.

To date there is no specific enzyme replacement therapy or approved gene therapy, but GDE enzyme replacement therapy modeled on the success of ERT for Pompe disease and AAV-based gene therapy are being studied at the preclinical stage. The observation that a high-protein diet supplies gluconeogenic precursors, improving hypoglycemia and also contributing to muscle protection, has formed the basis of clinical dietary therapy since the 1990s.


2. Causes

Cori disease/Forbes disease (GSD type III) is an autosomal recessive genetic disorder caused by deficiency of the glycogen debranching enzyme (GDE) due to pathogenic variants in the AGL gene. GDE is a key enzyme in glycogen breakdown; when glycogen phosphorylase cleaves α-1,4 bonds and stops at a branch point, GDE processes it to complete the breakdown.

GDE has two enzymatic activities in a single polypeptide (1532 amino acids). ① Oligo-1,4→1,4-glucan transferase activity (4-α-glucanotransferase): transfers the 3 glucose residues just before the branch point to an adjacent linear chain. ② Amylo-1,6-glucosidase activity: hydrolyzes the single glucose residue at the branch point (α-1,6 bond), releasing it as free glucose. Both activities or only one may be deficient, constituting the subtypes.

GSD subtype classification: GSD IIIa — GDE deficiency in both liver and muscle (about 80% of the total). GSD IIIb — GDE deficiency in the liver only, normal muscle GDE (about 15%; mainly associated with exon 3 variants). GSD IIIc — deficiency of amylo-1,6-glucosidase activity only (very rare). GSD IIId — deficiency of oligoglucan transferase activity only (very rare).

Because of GDE deficiency, phosphorylase can break down glycogen only to a distance of about 4 glucose residues from the branch points, after which glycogen with abnormally short outer chains, called limit dextrin, accumulates in the liver, muscle, and myocardium. Because gluconeogenesis itself is normal (unlike GSD I, G6Pase function is normal), blood glucose can be partly maintained by gluconeogenesis during prolonged fasting, so hypoglycemia is milder than in GSD I. Also, because the gluconeogenic response to glucagon after meals is normal, a rise in blood glucose upon postprandial glucagon stimulation is an important point of distinction from GSD I (no response to glucagon).


3. Genetics

The AGL gene is located on chromosome 1p21.2, is about 85 kb in total size, and consists of 35 exons. The translation product is a large multifunctional enzyme of 1532 amino acids, with the oligoglucan transferase activity domain at the N-terminus and the amylo-1,6-glucosidase activity domain at the C-terminus. More than 200 pathogenic AGL variants have been reported worldwide, including various variant types such as missense, nonsense, splicing, small deletions/insertions, and large exon deletions.

Correlation between subtype and genotype: GSD IIIb is characteristically associated with variants in exon 3 in particular (c.17_18delAG, etc.); because exon 3 is a region included in a transcript (mRNA isoform) expressed only in muscle, when this variant is present, liver GDE is deficient but muscle GDE is maintained through the normal isoform. Therefore, there is no muscle involvement in GSD IIIb. Most other variants cause loss of function in both liver and muscle, presenting as GSD IIIa.

Founder variants: in North African Jews (Sephardic/Moroccan Jewish), c.16C>T (p.Q6X, premature termination in exon 3) is found at a very high frequency, and the prevalence of GSD III in this group is high at about 1/5,400. A specific founder variant (IVS32-12A>G) has also been reported in the Inuit population. Systematic research on the Korean-specific variant spectrum is limited, but Korean molecular epidemiological data are accumulating in patients diagnosed with GSD III.

Limitations of phenotype prediction: even among patients with the same variant, there is considerable individual variation in the severity of myopathy and whether cardiomyopathy is present. This is presumed to be because genetic modifier effects, metabolic environment, level of physical activity, and the like influence the phenotype. Therefore, it is difficult to fully predict muscle involvement from genotype alone, and combined clinical and enzyme testing is recommended.

Molecular genetic testing for diagnosis and counseling: complete analysis of the AGL gene (NGS-based panel or WES) is the current standard, together with copy number variant (CNV) analysis. After the familial variant is identified, carrier testing and prenatal diagnosis are possible. Confirmation of the variant type (IIIa- vs. IIIb-associated variants) directly affects planning of cardiac and muscle monitoring.


4. General epidemiology

The overall prevalence of Cori disease (GSD type III) is estimated at about 1 in 100,000 births, and it is the second most common subtype of all glycogen storage diseases (after GSD I). It is reported worldwide, with no difference in frequency by sex. GSD IIIa (liver + muscle involvement) accounts for about 80% of the total and GSD IIIb (liver involvement only) about 15%, while IIIc and IIId are each rare.

Ethnicity-specific prevalence: in North African Jews (including Moroccan Jews), the prevalence of GSD III is about 1/5,400, about 20 times higher than in the general population, reflecting the high carrier frequency of the c.Q6X founder variant. In this group, GSD III is a rare disease of public health importance. A high prevalence due to a specific founder variant (IVS32-12A>G) has also been reported in the Inuit Alaska Native population.

Accurate prevalence data for GSD III in Korea are limited, but diagnosed cases are steadily reported from pediatric metabolic clinics and endocrine centers. Because the clinical picture of GSD III is similar to GSD I, differential diagnosis is needed, and some cases are initially misdiagnosed as GSD I and then rediagnosed as GSD III on enzyme testing or genetic analysis. Patients registered with GSD III in Korea receive Special Copayment Reduction (V117) and are managed at specialized metabolic disease centers.

GSD III tended to be recognized only as a simple childhood liver disease, with follow-up often neglected after adulthood, but as long-term follow-up studies have reported adult myopathy (GSD IIIa) and liver fibrosis → cirrhosis → hepatocellular carcinoma (all subtypes), the importance of continuous follow-up into adulthood is being emphasized. In multinational cohort studies in Europe and the United States, liver fibrosis was found in about 40–50% of adult GSD III patients.


5. Pathophysiology

The core pathophysiology of Cori disease (GSD type III) is incomplete termination of glycogen breakdown due to deficiency of the glycogen debranching enzyme (GDE). In normal glycogen breakdown, phosphorylase cleaves α-1,4 bonds from the ends and stops about 4 residues before a branch point (α-1,6 bond). The transferase activity of GDE then moves the 3 glucose residues just before the branch point to an adjacent linear chain, and the amylo-1,6-glucosidase activity releases the remaining single branch glucose as free glucose. This removes the branch structure so that phosphorylase can resume breakdown up to the next branch.

When GDE is deficient, phosphorylase acts partially but branch points cannot be processed, so glycogen with abnormally short outer chains called limit dextrin accumulates. This limit dextrin glycogen is a structure with more branches than normal glycogen and accumulates in cells without being converted into functional glucose.

Comparison with GSD I: in GSD III, G6Pase function is normal, so the gluconeogenic pathway (pyruvate → phosphoenolpyruvate → ... → G6P → glucose) works fully. Therefore, during prolonged fasting, a certain level of blood glucose can be maintained when gluconeogenic precursors such as amino acids (aspartate, alanine), lactate, and glycerol are supplied. Also, during short fasting, phosphorylase breaks down part of the outer chains of limit dextrin and can supply some glucose. For these reasons, hypoglycemia in GSD III is milder and occurs later than in GSD I, and may be accompanied by ketosis (whereas ketosis is very rare in GSD I).

Muscle and myocardial pathophysiology: in GSD IIIa, limit dextrin accumulation due to GDE deficiency also occurs in skeletal muscle and myocardium. Progressive accumulation of limit dextrin within muscle fibers disrupts muscle fiber structure and damages contractile proteins, causing progressive myopathy. Limit dextrin accumulation in the myocardium can cause hypertrophic or dilated cardiomyopathy, progressing to heart failure in severe cases. In childhood, there are often no heart failure symptoms even with myocardial hypertrophy, but a pattern of declining cardiac function appearing in adulthood is observed.

Mechanism of liver fibrosis: chronic cell injury, ER stress, and activation of inflammatory signaling pathways due to limit dextrin accumulation in hepatocytes continuously stimulate hepatic stellate cells, leading to collagen deposition and progressive fibrosis. In the long term, the risks of cirrhosis and the resulting portal hypertension and hepatocellular carcinoma increase. The observation that reducing glycogen accumulation through dietary management can suppress the progression of liver fibrosis is an important basis for clinical dietary therapy.


6. Symptoms

The clinical symptoms of Cori disease (GSD type III) change with age and are characterized by a biphasic course in which liver symptoms predominate in childhood and myopathy and cardiomyopathy come to the fore in adulthood.

Symptoms in infancy and childhood: hepatomegaly and abdominal distension appear from a few months of age, and fasting hypoglycemia develops. Unlike GSD I, the degree of hypoglycemia is mostly mild to moderate, and serum lactate is normal or only slightly elevated. Ketonemia sometimes accompanies it, providing a clue that distinguishes it from GSD I (no ketosis). Serum CK is elevated (in GSD IIIa), a finding not seen in GSD I. Growth retardation and global developmental delay may appear but are often milder than in GSD I. Elevated serum aminotransferases (AST, ALT) are common.

Symptoms in adolescence to adulthood (GSD IIIa): hepatomegaly tends to decrease spontaneously in adolescence, and hypoglycemia mostly disappears in adulthood. However, from this period, progressive proximal muscle weakness gradually comes to the fore. The quadriceps, proximal upper limb muscles, and erector spinae are mainly affected, and climbing stairs and lifting heavy objects become difficult. Exercise intolerance and a tendency to tire easily appear. Cardiomyopathy: hypertrophic (HCM) or dilated (DCM) cardiomyopathy may develop, and palpitations, exertional dyspnea, and edema may appear. Because the asymptomatic period is long, it is sometimes discovered incidentally in adulthood or first diagnosed as heart failure.

Symptoms of GSD IIIb: childhood hepatomegaly and hypoglycemia are the main symptoms, with no muscle symptoms. Liver symptoms partly improve after adolescence, but the risk of liver fibrosis persists. Adult cirrhosis and hepatocellular carcinoma have also been reported in IIIb, so periodic imaging follow-up is needed.


7. Signs

The most important finding on physical examination is hepatomegaly in infancy and childhood. The lower edge of the liver is palpable several cm below the umbilicus, or 10 cm or more in severe cases; the texture is soft and there is no tenderness. Splenomegaly is uncommon, but when the disease has progressed to cirrhosis, splenomegaly and ascites may develop.

Blood test findings: serum CK elevation is a characteristic finding of GSD IIIa, rising to 3–10 times normal along with liver AST and ALT. Fasting hypoglycemia (blood glucose around 50–60 mg/dL, milder than the 30 mg/dL of GSD I), elevated ketone bodies (unlike GSD I), serum lactate normal or slightly elevated (in contrast to the marked lactic acidosis of GSD I). Serum uric acid lower than in GSD I or normal. Triglyceride elevation mild or absent. Serum amino acids (aspartate, alanine): may decrease due to use for gluconeogenesis, which is the basis for a high-protein diet.

Muscle signs (GSD IIIa): proximal muscle weakness — difficulty rising from a chair, positive Gowers sign. Myopathic pattern on electromyography (EMG). Muscle biopsy shows PAS-positive glycogen accumulation (vacuolar fibers).

Cardiac signs: left ventricular hypertrophy pattern and increased voltage on ECG. Ventricular wall thickening (hypertrophic cardiomyopathy) or left ventricular dilation with reduced ejection fraction (dilated cardiomyopathy) on echocardiography. A heart murmur may be heard on auscultation.

Liver imaging findings: increased echogenicity (fat deposition and glycogen accumulation) and hepatomegaly on liver ultrasound. With progression of liver fibrosis after adulthood, heterogeneous echogenicity, irregular liver surface, and splenomegaly. Differentiation of hepatocellular carcinoma lesions on liver MRI or ultrasound is needed. Liver biopsy is used to assess the degree of fibrosis, but because it is invasive, noninvasive fibrosis assessment (FIB-4, liver elastography = fibroscan) is used first.


8. Screening

Standardized universal newborn screening for Cori disease (GSD type III) is not performed. Early clinical diagnosis through clinical symptoms and biochemical findings is the realistic approach. Because the clinical picture of GSD III is similar to GSD I, understanding the differences in the fasting metabolic profile is important for early screening.

Clinical screening clues: ① fasting hypoglycemia in infants and children with hepatomegaly. ② Hypoglycemia with normal or slightly elevated serum lactate (an important distinction from GSD I). ③ Accompanying ketonemia (rare in GSD I). ④ Elevated serum CK (normal in GSD I). ⑤ Partial rise in blood glucose possible after glucagon stimulation (postprandial; complete lack of response in GSD I). This combination of patterns strongly suggests GSD III.

Family history-based screening: in families who have had a child with GSD III, early confirmation is possible in the next pregnancy by prenatal genetic diagnosis (CVS or amniocentesis). Early diagnosis by biochemical tests and enzyme/genetic testing is also recommended in asymptomatic siblings.

Screening for GSD III in adults with myopathy: in adults with unexplained proximal muscle weakness and CK elevation, if there is a past history of childhood hepatomegaly or hypoglycemia, GSD IIIa should be actively included in the differential diagnosis. It is confirmed by measurement of leukocyte GDE enzyme activity or AGL gene analysis. GSD III is one of the rare causes of adult myopathy that must be differentiated from Pompe disease, amyotrophic lateral sclerosis (ALS), lymphoma-related myopathy, polymyositis, and the like.


9. Diagnosis

The diagnosis of Cori disease (GSD type III) proceeds in the order of clinical-biochemical findings, measurement of enzyme activity, and molecular genetic confirmation.

Biochemical tests: fasting hypoglycemia (mild to moderate), ketonemia, CK elevation (GSD IIIa), AST/ALT elevation, mild triglyceride elevation (lower than GSD I), normal lactate (or slight elevation). Glucagon stimulation: when given in the postprandial state, blood glucose may rise (due to normal gluconeogenic function; the key distinction from GSD I). Glucagon stimulation in the fasting state may produce no or a weak glucose response (no further breakdown of limit dextrin after the phosphorylase limit is reached). Decreased blood amino acids (Asp, Ala): suggests active use for gluconeogenesis and is the biochemical basis for the need for a high-protein diet.

Enzyme activity tests: measurement of GDE activity in leukocytes or muscle tissue is the confirmatory method. Measurement of GDE activity in erythrocytes is also possible but less accurate. The diagnosis is confirmed when GDE activity is markedly reduced (less than 10% of normal). In GSD IIIb, muscle GDE is normal and only liver GDE is reduced, so muscle specimens give normal results, and liver biopsy or leukocyte testing is needed. GDE activity in leukocytes reflects GDE deficiency in both liver and muscle and is therefore suitable for diagnosing GSD IIIa.

Molecular genetic confirmation: NGS-based complete analysis of the AGL gene (35 exons + intron boundaries + CNV) confirms biallelic pathogenic variants. Identification of an exon 3 variant suggests GSD IIIb. If no variant is identified, copy number variant analysis is added. Molecular confirmation of GSD III is essential for subtype determination, muscle monitoring planning, genetic counseling, and family testing.

Liver biopsy and histology: performed selectively to assess glycogen accumulation in hepatocytes (PAS-positive, disappearing after diastase digestion), limit dextrin structure (electron microscopy), and the degree of fibrosis (Metavir or Ishak fibrosis score). For fibrosis assessment, noninvasive methods (FIB-4, liver elastography = fibroscan) are preferred.

Cardiac and muscle assessment: 12-lead ECG, echocardiography (baseline assessment after GSD IIIa diagnosis and regular follow-up). Electromyography (EMG), muscle strength measurement, 6-minute walk test (adult GSD IIIa). Pulmonary function tests (to check for respiratory muscle involvement).


10. Treatment

There is currently no specific enzyme replacement therapy or approved drug treatment for Cori disease (GSD type III), and dietary therapy and symptomatic treatment are the main treatments.

Dietary therapy — childhood: uncooked cornstarch (UCCS) is given regularly to prevent fasting hypoglycemia. Dietary therapy for GSD III is similar to that for GSD I, but restriction of simple sugars is less strict (because fructose and lactose can also be converted via gluconeogenesis in GSD III). Frequent meals and nighttime uncooked cornstarch minimize fasting periods. In GSD III, a high-protein diet is particularly recommended, because amino acids (especially aspartate and alanine) contribute to maintaining blood glucose as gluconeogenic precursors and also serve as substrates for muscle protein synthesis. Raising protein intake to about 2–3 g/kg body weight/day is recommended.

Treatment of adult myopathy: because there is no specific therapeutic agent, physical therapy, resistance exercise of appropriate intensity, and aerobic exercise help maintain muscle strength. Excessive exercise can worsen muscle damage, so it is adjusted to individual exercise tolerance. A high-protein diet is maintained in adulthood as well.

Treatment of cardiomyopathy: in hypertrophic cardiomyopathy, beta-blockers and calcium channel blockers may be used. When dilated cardiomyopathy and heart failure develop, standard heart failure drug therapy such as ACE inhibitors (or ARBs), beta-blockers, and diuretics is applied. When arrhythmias such as ventricular tachycardia occur, electrophysiological study and consultation with a cardiologist are needed. In rare cases of severe deterioration of cardiac function, heart transplantation has been considered.

Treatment of liver complications: for liver fibrosis/cirrhosis, standard cirrhosis management (portal hypertension, prophylactic treatment of esophageal varices, ascites management) is applied. When hepatocellular carcinoma develops, surgical resection, transarterial chemoembolization (TACE), ablation, and the like are considered. When liver failure is severe, liver transplantation is performed; after liver transplantation, the liver symptoms are corrected, but the myopathy and cardiomyopathy of GSD IIIa persist (because liver transplantation does not correct GDE in muscle).

Gene therapy research: AAV-based AGL gene transfer therapy is under study in preclinical animal models. Clinical successes of gene therapy for GSD I and Pompe disease are stimulating the development of GSD III gene therapy, and entry into clinical trials is expected in the future.


11. Prognosis

The prognosis of Cori disease (GSD type III) varies with the subtype and the occurrence of long-term complications. Overall, life expectancy is better than in GSD I, but it follows a chronic course in which multi-organ complications accumulate in adulthood.

Prognosis in childhood: when hypoglycemia is adequately controlled with dietary therapy, growth and development proceed relatively normally. Some patients show delayed intellectual development in childhood, but when hypoglycemia is well controlled, the neurodevelopmental prognosis is good. Hepatomegaly tends to improve spontaneously in adolescence.

Prognosis of adult myopathy (GSD IIIa): proximal muscle weakness worsens progressively, and walking aids (walker, wheelchair) are sometimes needed after middle age. Scoliosis and reduced respiratory function due to erector spinae weakness may develop. In a European cohort study (Sentner et al., 2016), about 75% of adult GSD IIIa patients experienced muscle weakness in adulthood.

Prognostic impact of cardiomyopathy: hypertrophic cardiomyopathy is a risk factor for heart failure or sudden cardiac death. Because cardiomyopathy is sometimes first identified or worsens in adulthood, regular cardiac follow-up is key to determining prognosis.

Liver prognosis: progression from liver fibrosis to cirrhosis is reported in about 15–20% of patients, and hepatocellular carcinoma develops in some. Hepatocellular carcinoma has also been reported to occur regardless of the presence of cirrhosis, so regular imaging surveillance is recommended even in non-cirrhotic livers.

Prognosis of GSD IIIb: because there is no muscle involvement, there is no myopathy-related morbidity, but the risk of liver complications (fibrosis, cirrhosis, hepatocellular carcinoma) persists, similar to IIIa.


12. Prevention

The key to prevention of Cori disease (GSD type III) is preventing complications through genetic counseling and early diagnosis. Primary prevention: affected births can be prevented through carrier testing within the family, prenatal genetic diagnosis, and PGT. Secondary prevention: prevention of hypoglycemia and minimization of liver and muscle glycogen accumulation through dietary therapy (high protein, uncooked cornstarch). Tertiary prevention: early detection of and therapeutic intervention for cardiomyopathy, liver fibrosis, and myopathy.

Education on preventing hypoglycemic emergencies: patients and caregivers are educated on recognizing hypoglycemia and emergency measures (oral glucose, criteria for emergency admission). Sharing emergency response methods with schools and workplaces is also important.

Cardiac monitoring: from the diagnosis of GSD IIIa, regular ECG and echocardiography are performed to detect asymptomatic cardiomyopathy early. When cardiomyopathy is confirmed, standard heart failure management protocols are applied early to prevent deterioration of cardiac function.

Liver monitoring: liver ultrasound is performed every 6 months to 1 year to monitor liver size, echogenicity, signs of fibrosis, and nodular lesions (hepatocellular carcinoma). In adulthood, liver elastography (fibroscan) and AFP measurement are performed periodically. Patients are educated to abstain from alcohol and minimize the use of hepatotoxic drugs.


13. References

  1. Sentner CP, Hoogeveen IJ, Weinstein DA, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39(5):697-704. DOI: 10.1007/s10545-016-9932-2. PMID: 27106402.
  2. Kishnani PS, Austin SL, Arn P, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446-463. DOI: 10.1097/GIM.0b013e3181e655b6. PMID: 20631546.
  3. Dagli AI, Weinstein DA. Glycogen storage disease type III. In: Adam MP, et al. eds. GeneReviews. Seattle: University of Washington; 2009 (Updated 2021). PMID: 20301788.
  4. Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta Myol. 2007;26(1):72-74. PMID: 17915579.
  5. Brunberg JA, McCormick WF, Schochet SS. Type III glycogenosis: an adult with diffuse weakness and muscle wasting. Arch Neurol. 1971;25(2):171-178. DOI: 10.1001/archneur.1971.00490020057008. PMID: 4327042.
  6. Demo E, Bhatt A, Roberts R, Phan A. Glycogen storage disease type IIIa: a case series examining the effects of modified Atkins diet on hypoglycemia and cardiomyopathy. JIMD Rep. 2019;47(1):24-29. DOI: 10.1002/jmd2.12035. PMID: 31240153.
  7. Endo Y, Gondo K, Noguchi S, et al. Molecular genetic studies of Japanese patients with glycogen storage disease type III. J Hum Genet. 2006;51(5):399-406. DOI: 10.1007/s10038-006-0383-5. PMID: 16607545.
  8. Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24(3):276-279. DOI: 10.1097/00005176-199703000-00008. PMID: 9138171.
  9. Aoyama Y, Komaki H, Iida A, et al. A novel muscle glycogen debranching enzyme mutation in a Japanese patient with glycogen storage disease type IIIa. Mol Genet Metab Rep. 2019;19:100476. DOI: 10.1016/j.ymgmr.2019.100476. PMID: 31193367.
  10. Goldstein JL, Austin SL, Boyette K, et al. Myopathy in late-onset Pompe disease and glycogen storage disease type III: a common clinical presentation, distinct mechanisms, and different treatment approach. Mol Genet Metab. 2009;97(4):291-294. DOI: 10.1016/j.ymgme.2009.04.006. PMID: 19447680.